The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
F8 · 1-44
The story of tesamorelin is inseparable from the story of a metabolic catastrophe that emerged in the late 1990s. When highly active antiretroviral therapy (HAART) transformed HIV from a death sentence into a manageable chronic disease, a new and unexpected complication appeared in many of the patients whose lives had been saved: profound, disfiguring, metabolically dangerous fat redistribution that reshaped how HIV care looked for the following two decades.
HIV-associated lipodystrophy is a complex metabolic syndrome characterized by two parallel fat distribution abnormalities. The first is peripheral fat wasting — subcutaneous fat loss from the face (creating the characteristic sunken cheeks and visible facial bones), limbs, and buttocks. The second is central fat accumulation — visceral fat deposits deep in the abdomen, breast enlargement, and fat pads at the base of the neck (the 'buffalo hump'). Both changes appear to be driven primarily by the antiretroviral drugs themselves — particularly the earlier protease inhibitors and nucleoside reverse transcriptase inhibitors — rather than by HIV infection itself. The metabolic consequences: dyslipidemia (elevated triglycerides, reduced HDL), insulin resistance, and markedly elevated cardiovascular risk in a population that was now surviving long enough to develop cardiovascular disease.
The growth hormone axis connection: patients with HIV-associated lipodystrophy show reduced pulsatile GH secretion — pituitary GH release is blunted, pulsatility is reduced, and the resulting reduction in circulating IGF-1 promotes visceral fat accumulation in a pattern that mirrors somatopause. Theratechnologies, a Montreal-based biopharmaceutical company, recognized this GH axis disruption as a pharmacological target: if HAART was suppressing GH pulsatility and thereby promoting visceral fat accumulation, a GHRH analog that restored pulsatile GH might reverse the fat redistribution.
The development challenge was pharmacokinetic. Native GHRH is degraded rapidly in plasma by dipeptidyl peptidase IV (DPP-IV), an enzyme that cleaves the first two amino acids from GHRH's N-terminus — a cleavage that renders the peptide biologically inactive within minutes. Sermorelin, as a 1-29 fragment with the same L-amino acid N-terminus, shares this vulnerability. Theratechnologies' solution: conjugate a trans-3-hexenoic acid group to the N-terminal tyrosine of full-length GHRH(1-44). The aliphatic chain modification provides steric protection against DPP-IV cleavage without disrupting GHRH receptor binding geometry. The result was a compound with a functional half-life of 26-38 minutes — substantially longer than sermorelin, sufficient for once-daily SubQ administration, and with GHRH receptor biology preserved.
Two large Phase 3 trials followed. LIPO-010 (n=412) and CTR-1011 (n=404) were both randomized, double-blind, placebo-controlled multicenter trials in HIV-positive adults with confirmed lipodystrophy and excess visceral fat. Both showed statistically significant and clinically meaningful visceral adipose tissue reduction at 26 weeks with 2 mg/day tesamorelin. FDA approved tesamorelin (Egrifta) in November 2010 — the first and, as of 2026, only GHRH analog to achieve full FDA drug approval. Reformulations followed: Egrifta SV (2019) reduced injection complexity; Egrifta WR/F8 (March 2025) reduced reconstitution burden to weekly while maintaining daily injection.
THE CENTRAL TENSION
Tesamorelin's FDA approval is the strongest regulatory validation of any GHRH analog — two large Phase 3 RCTs, a Lancet HIV NAFLD trial showing 37% liver fat reduction and fibrosis prevention, a cognitive function trial. But the approval is narrow and population-specific: HIV-positive adults with lipodystrophy caused by antiretroviral therapy. The Phase 3 trials enrolled a phenotypically specific population with disrupted GH secretion secondary to HIV/HAART. Community use extends this to otherwise healthy adults with garden-variety visceral obesity, somatopause, or general body composition goals. The compound's own prescribing label explicitly states it 'is not indicated for weight loss management as it has a weight-neutral effect.' The gap between the approved population and the community off-label population is pharmacologically meaningful — and regularly obscured by anti-aging clinic marketing.
The safety database for tesamorelin is more extensive than for almost any other compound in this book — over 800 patients in Phase 3 trials alone, with extension data beyond 52 weeks. This is a genuine strength of the compound's regulatory history.
Arthralgia/joint pain: most commonly reported adverse event; dose-dependent; consistent with GH-mediated effects on periarticular tissue and bone; occurs in approximately 15-20% of patients in Phase 3 trials vs ~8-10% placebo. Injection site reactions: erythema, pruritus, pain; common; mild; typical for protein subcutaneous injection. Peripheral edema: GH-mediated sodium and water retention; dose-dependent; generally mild and self-limiting. Muscle pain/myalgia: GH-related; consistent with changes in muscle metabolism. Peripheral neuropathy/tingling: reported; consistent with carpal tunnel-equivalent from soft tissue fluid retention. These side effects are well-characterized, dose-dependent, and generally manageable.
Glucose and HbA1c: modest elevations observed in a subset of patients across Phase 3 trials. The mechanism: GH induces relative insulin resistance at the adipocyte and liver level (lipolysis releases free fatty acids that compete with glucose for energy metabolism). This glucose effect is dose-dependent and generally within the range of modest clinical significance — increases in HbA1c of 0.2-0.4% were observed. Not a contraindication in most patients but: baseline glucose and HbA1c assessment mandatory; periodic monitoring during therapy; caution in pre-diabetic or diabetic patients where even modest glucose deterioration may be clinically significant. The prescribing label recommends glucose monitoring.
ACTIVE MALIGNANCY — CONTRAINDICATION
Tesamorelin carries the same active malignancy contraindication as all GH axis-stimulating compounds, with the added weight of FDA label specificity: the prescribing information explicitly states that tesamorelin is contraindicated in patients with active malignancy. The mechanism: IGF-1 elevation (documented approximately 81% increase from baseline in Phase 3 trials) can promote tumor cell survival and proliferation via IGF-1R in IGF-1R-expressing malignancies. Active malignancy: absolute contraindication. History of malignancy with IGF-1R-sensitive histology: physician consultation required. The somatostatin ceiling limits the maximum IGF-1 elevation that tesamorelin can produce — the risk is lower than with exogenous rhGH at high doses, but the concern applies nonetheless.
The original prescribing information categorized tesamorelin as Pregnancy Category X (FDA category system): the drug should not be used during pregnancy. Rationale: visceral fat reduction is not a therapeutic priority during pregnancy; growth hormone axis perturbation during fetal development carries unknown risks; no adequate human pregnancy data exists. Not relevant to most anti-aging protocol users but an important clinical note for any woman of childbearing potential considering off-label use.
The F8 formulation approval (March 2025) is a convenience improvement rather than a pharmacological change. Egrifta WR requires reconstitution once weekly (instead of daily) and injection volume of less than half of Egrifta SV. Bioequivalence to the original F1 formulation was confirmed in pharmacokinetic studies. For patients prescribed tesamorelin for the approved HIV indication, this represents a meaningful adherence improvement — reconstitution daily while managing HIV medications and other aspects of chronic disease care is a real burden. For off-label users, the weekly reconstitution is similarly convenient.
Tesamorelin: GHRH(1-44) with trans-3-hexenoic acid conjugated to the N-terminal tyrosine via an amide bond. This means tesamorelin is the complete 44-amino acid GHRH sequence — unlike sermorelin (29 aa) or CJC-1295 (29 aa with modifications). The trans-3-hexenoic acid modification at the N-terminus does not alter GHRH receptor binding affinity — the receptor interaction domain of GHRH is primarily within the first 29 amino acids. The modification specifically disrupts DPP-IV recognition at the N-terminal Tyr-Ala sequence, preventing the enzymatic cleavage that would otherwise inactivate the peptide within minutes of entry into the bloodstream. MW approximately 5135 Da. This larger molecular weight vs sermorelin (~3358 Da) or CJC-1295 (~3368 Da) reflects the full 44-amino acid length.
Half-life: ~26-38 minutes following subcutaneous injection — the longest half-life of any non-albumin-binding GHRH analog used in clinical practice. This is substantially longer than sermorelin's ~10-12 minutes but shorter than CJC-1295 with DAC (~5-8 days). The extended half-life from DPP-IV protection is sufficient for once-daily SubQ dosing to produce therapeutically meaningful GH stimulation throughout the day, particularly during the post-injection window. GH pulse peaks approximately 30-60 minutes after SubQ injection; returns toward baseline within 2-4 hours. Unlike CJC-1295 with DAC, tesamorelin does not produce continuous GHRH receptor stimulation — it produces a prolonged but still transient and pulsatile GH stimulus that preserves the somatostatin feedback architecture.
Compound
Structure
Half-life
GH Pattern
Key Feature
FDA Status
Sermorelin
GHRH(1-29), all L-amino acids
~10-12 min
Brief discrete pulse; most physiological
Shortest t1/2; most physiological; somatostatin ceiling preserved
Category 1 (reportedly); WADA banned
CJC-1295 (no DAC)
Modified GHRH(1-29); 4 AA substitutions
~30 min
Extended pulse vs sermorelin
Stable; no albumin binding; pulsatile preserved
Category 1 (reportedly); WADA banned
CJC-1295 (with DAC)
Modified GHRH(1-29) + albumin binding
~5-8 days
Near-continuous; non-pulsatile
Once/twice weekly dosing; FDA cited pituitary DNA damage signal
Uncertain; WADA banned
Tesamorelin (Egrifta)
GHRH(1-44); N-terminal trans-3-hexenoic acid
~26-38 min
Pulsatile; longer window than sermorelin
Only FDA-approved GHRH analog; full 44-aa sequence; DPP-IV protected
FDA-APPROVED (HIV lipodystrophy); WADA banned
Tesamorelin off-label
Same molecule
Same
Same
Used for non-HIV visceral fat, somatopause, cognition — not FDA-sanctioned
Off-label only for non-HIV uses
Tesamorelin binds GHRHR (growth hormone releasing hormone receptor) on anterior pituitary somatotroph cells via the same mechanism as endogenous GHRH — Gs protein coupling → adenylate cyclase → cAMP → PKA → GH gene transcription and secretory granule exocytosis. The full 44-amino acid sequence provides complete GHRHR interaction at both the N-terminal binding region (amino acids 1-29) and the C-terminal receptor stability region (amino acids 30-44). The somatostatin feedback architecture is fully preserved — when GH rises sufficiently, hypothalamic somatostatin release increases and dampens the pituitary's GHRHR response. This means tesamorelin cannot produce supraphysiological GH in a sustained manner — the same physiological ceiling that applies to sermorelin applies equally. The difference from native GHRH is pharmacokinetic only: DPP-IV protection extends the active window from minutes to ~30-60 minutes.
The specific selectivity of GH and IGF-1 for visceral adipose tissue over subcutaneous fat is the defining pharmacological feature driving tesamorelin's clinical application. Visceral adipocytes (fat cells surrounding internal organs) have higher density of beta-adrenergic receptors and are more sensitive to lipolytic stimulation than subcutaneous adipocytes. GH activates beta-adrenergic signaling and promotes free fatty acid release preferentially from visceral stores via: (1) GH receptor activation on visceral adipocytes → JAK2/STAT5 → hormone sensitive lipase (HSL) activation; (2) IGF-1-independent direct effects of GH on adipocyte metabolism. This mechanism is why GH deficiency states — including somatopause and HIV-associated GH axis suppression — are characterized by visceral fat accumulation, and why GH or GHRH restoration preferentially mobilizes visceral fat. Subcutaneous fat responds less dramatically to GH-mediated lipolysis.
The somatostatin feedback mechanism provides the same safety feature in tesamorelin as in sermorelin: when GH levels rise sufficiently from GHRH receptor stimulation, hypothalamic somatostatin release increases, blunting further GH secretion. This means tesamorelin cannot produce the sustained supraphysiological GH levels that exogenous rhGH can generate at high doses. The ceiling is lower because the pituitary itself limits the response. This is why the prescribing information notes that tesamorelin is 'weight-neutral' — it produces physiological GH elevation sufficient for visceral fat reduction in a GH-deficient population, but not the supraphysiological levels needed for substantial lean mass gains or general weight loss. In a normally GH-sufficient healthy adult, the increment of GH above baseline that tesamorelin can produce is smaller than in a GH-suppressed HIV patient.
The Lancet HIV NAFLD trial finding — 37% relative liver fat reduction with 12 months of tesamorelin in HIV-positive adults with NAFLD — involves additional mechanisms beyond simple visceral fat lipolysis. GH and IGF-1 directly regulate hepatic lipid metabolism: GH stimulates hepatic beta-oxidation (fat burning in the liver); GH reduces de novo lipogenesis (new fat synthesis in the liver) via insulin-independent mechanisms; GH promotes hepatic VLDL export, reducing hepatocellular fat accumulation. Visceral fat reduction itself reduces the delivery of free fatty acids to the portal circulation (the 'portal hypothesis' of NAFLD — visceral fat drains directly into the portal vein, flooding the liver with lipid substrate). The fibrosis prevention finding is mechanistically coherent: reducing hepatic fat and inflammation reduces the activation of hepatic stellate cells that drive fibrotic progression.
Tesamorelin's evidence base is extraordinary within its approved indication and substantially thinner outside it. The correct interpretation of the FDA approval is that it validates tesamorelin's safety and efficacy in HIV lipodystrophy — not that it validates any generalization to other populations.
The pivotal evidence: Falutz J et al. (2010, JCEM) pooled analysis of LIPO-010 (n=412) and CTR-1011 (n=404). Both double-blind, randomized, placebo-controlled. Both showing statistically significant VAT reduction by CT scan at 26 weeks. Pooled results: mean VAT reduction of approximately 17% vs placebo; IGF-1 increase of approximately 81%; significant lean body mass gain; significant triglyceride reduction. A separate safety extension study (Falutz 2008, AIDS) documented tolerability with continued treatment beyond 52 weeks. These are genuine Phase 3 trials with sample sizes (n>400 each) and design rigor (double-blind, placebo-controlled, CT-measured primary endpoint) that most peptides in this book do not come close to matching. The evidence is Grade A within this specific population.
What the Phase 3 trials do not show: they do not show comparable VAT reduction in healthy adults without HIV-associated GH axis suppression; they do not show meaningful body weight reduction (the compound is weight-neutral as stated in the prescribing label); they do not show that the metabolic benefits generalize to non-HIV visceral obesity. The population enrolled — HIV-positive patients with documented lipodystrophy and GH axis disruption — is pharmacologically distinct from otherwise healthy adults using tesamorelin off-label for somatopause or general body composition.
Stanley TL, Feldpausch MN, Oh J et al. (Lancet HIV, 2019): n=61 HIV-positive adults with hepatic fat fraction ≥5% by magnetic resonance spectroscopy; randomized 1:1 to tesamorelin 2 mg/day vs placebo for 12 months. Primary endpoint: change in hepatic fat fraction. Results: tesamorelin reduced hepatic fat fraction by an absolute 4.1% (95% CI -7.6, -0.7; p=0.02), corresponding to a 37% relative reduction. Secondary finding: fibrosis progression occurred in only 10% of tesamorelin-treated patients vs 35% in placebo. These are striking results in a condition (HIV-associated NAFLD) where no other pharmacological treatment has demonstrated comparable efficacy. The fibrosis prevention finding — one of the most clinically important outcomes in hepatology — achieved in a population with no other proven treatment options. Grade A within HIV-associated NAFLD specifically.
Baker LD et al. (2012, JAMA Neurology): controlled trial of GHRH analog therapy in older adults (55+) — some with mild cognitive impairment, some healthy — for 20 weeks. Executive function measured by a computerized battery. Result: GHRH therapy produced favorable effects on cognition in adults with mild cognitive impairment and healthy older adults; the improvement was attributed to GH/IGF-1 axis restoration. A 2024 HIV-specific cognitive trial did not replicate the cognitive findings in an HIV population. Grade B: one positive trial, inconsistent replication, active research area. The cognitive benefit claim requires the honest qualification that one positive trial in older adults has not been consistently replicated.
The question most longevity clinic patients are implicitly asking — 'does tesamorelin reduce visceral fat in healthy adults without HIV?' — has limited controlled evidence. One 2025 study in non-HIV adults with metabolic syndrome explored tesamorelin's effects on visceral fat in this population; preliminary data was generally positive in direction. This remains Grade B at best — one study, small sample, not yet peer-reviewed as of 2026. The mechanism is plausible: somatopause causes GH axis suppression in aging adults similarly to HIV/HAART-induced suppression; tesamorelin should restore pulsatile GH and drive visceral fat reduction through the same mechanism. But plausible mechanism ≠ established efficacy, and the magnitude of effect in a partially GH-suppressed aging adult without the specific HIV phenotype may be substantially smaller than the 15-18% VAT reduction observed in the Phase 3 trials.
Claim
Grade
Evidence
Honest Assessment
VAT reduction 15-18%: HIV lipodystrophy
A
LIPO-010 (n=412) + CTR-1011 (n=404); DBRPCT; 26 weeks; Falutz 2010 JCEM
FDA-approved; Phase 3; strongest GHRH analog visceral fat evidence
Liver fat reduction -37%, fibrosis prevention
A
Stanley/Grunfeld 2019 Lancet HIV; n=61; DBRPC; 12 months
Only proven pharmacological treatment for NAFLD in HIV; Grade A within this narrow population
IGF-1 elevation ~81%, lean mass increase
A
Phase 3 pooled data; consistent across trials
Well-established in HIV lipodystrophy population
Weight-neutral (not a weight loss drug)
A
FDA prescribing label explicit statement
Frequently obscured in community/clinic marketing
Cognitive improvement (older adults)
B
Baker 2012 JAMA Neurology; positive; 2024 HIV trial negative
Inconsistent replication; active research area
VAT reduction: non-HIV healthy adults
B
One small 2025 preliminary study; mechanism plausible
Not yet established by controlled evidence at Phase 3 level
Body composition: non-HIV off-label population
B
Mechanism-based extrapolation; limited controlled data
Not the approved population; evidence significantly thinner
Glucose/HbA1c elevation (safety)
A
Phase 3 data; subset of patients; dose-dependent
Real signal; monitoring required
Standard dose: 2 mg/day SubQ injection. The Phase 3 trials used 2 mg/day (approximately 0.03 mg/kg for a 70 kg person). The same dose is used in the NAFLD trial and in the cognitive function research. No titration required in the approved indication — 2 mg/day is the target and therapeutic dose. Injection: SubQ; abdomen preferred site; rotate injection sites. Timing: typically administered in the evening or before sleep to align with the natural nocturnal GH pulse — the same circadian rationale as all GHRH analogs.
When physicians prescribe tesamorelin off-label for visceral fat reduction, body composition, somatopause, or general anti-aging in non-HIV patients, they typically use the same 2 mg/day dose — because that is the dose studied in the pivotal trials and the dose for which safety data exists. Some anti-aging practitioners use lower doses (1 mg/day) in patients with good baseline GH function, reasoning that the GH increment needed in a partially GH-suppressed aging adult is smaller than in an HIV patient with more pronounced GH axis disruption. Neither approach has been validated in controlled trials in the off-label population.
Lab/Assessment
Timing
Rationale
Action If Abnormal
Baseline IGF-1
Before starting
Confirm GH axis status; establish baseline
If very low: confirms clinical rationale; if normal/high: reconsider indication
Fasting glucose / HbA1c
Before starting; q3-6 months
Glucose elevation documented in Phase 3; baseline essential
If pre-diabetic: additional caution; diabetic: contraindication assessment
IGF-1 on-therapy
At 4-6 weeks; q3-6 months
Target upper-normal range for age; avoid supraphysiological
Reduce dose or stop if persistently supraphysiological
LFTs (liver function)
Baseline
Particularly relevant in NAFLD-adjacent off-label use
Baseline for comparison
Clinical assessment
Ongoing
Arthralgia, edema, injection site reactions
Manage symptomatically; reduce dose if severe
Unlike GHRPs where receptor desensitization is a documented concern with continuous daily use, GHRHR downregulation from tesamorelin appears less pronounced at clinical doses — the Phase 3 extension trials documented continued efficacy beyond 52 weeks of treatment. The prescribing information's approach is continuous daily therapy with periodic reassessment. The community-derived cycling protocols (3 months on, 1 month off) that are common with GH secretagogues reflect caution imported from GHRP experience and the general longevity/anti-aging community's preference for non-continuous protocols. For the approved indication, continuous use is the clinical standard; for off-label use, both continuous and cycled protocols are used without comparative evidence.
The FDA approval of tesamorelin is the most frequently misrepresented fact in community discussions of this compound. Getting the distinction right matters — not as a regulatory technicality but because the approved population and the community population are genuinely pharmacologically different.
Partially true, misleadingly framed. Tesamorelin is FDA-approved for visceral fat reduction in HIV-positive adults with lipodystrophy caused by antiretroviral therapy. The approval is not for visceral fat reduction in general. The condition it was approved for — HIV-associated lipodystrophy — involves a specific pathophysiology (GH axis suppression from HAART drugs) that produces a characteristic visceral fat phenotype. The efficacy demonstrated in Phase 3 trials reflects treatment of this specific pathophysiology. Whether comparable VAT reduction occurs in otherwise healthy adults with age-related visceral obesity who do not have documented HAART-induced GH axis suppression has not been established by Phase 3 controlled evidence.
THE PRESCRIBING LABEL IS EXPLICIT — TESAMORELIN IS NOT A WEIGHT LOSS DRUG
The FDA prescribing information for tesamorelin contains the following statement: Egrifta WR 'is not indicated for weight loss management as it has a weight-neutral effect.' This is not a nuanced or ambiguous statement. It is in the label. The compound reduces visceral adipose tissue specifically — a redistribution of fat composition — but does not produce meaningful reduction in total body weight because visceral fat, while metabolically important, represents a relatively small fraction of total body fat. Users hoping for meaningful scale weight reduction from tesamorelin will be disappointed. Users hoping for reduction in abdominal girth and metabolic improvement from VAT reduction specifically are in the right frame for the compound's mechanism.
False equivalence. Tesamorelin is full-length GHRH(1-44) with N-terminal DPP-IV protection. CJC-1295 (no DAC) is a modified GHRH(1-29) fragment with 4 amino acid stability substitutions. CJC-1295 with DAC adds albumin binding for a multi-day half-life with fundamentally non-pulsatile GHRH receptor stimulation. These are pharmacologically distinct compounds with different half-lives, different GH pulse profiles, and different evidence bases. The FDA approval of tesamorelin does not extend to or validate CJC-1295 in any form.
Not a meaningful claim. The GHRH analogs do not differ in GHRHR binding affinity or pharmacodynamic effect at the receptor level — they differ in pharmacokinetic profiles (how long they stay active). Tesamorelin's full 44-amino acid sequence does not produce a stronger GHRHR signal per active molecule than sermorelin's 29-amino acid fragment. The 'potency' difference between GHRH analogs is pharmacokinetic (duration of GHRHR stimulation per dose) not pharmacodynamic (receptor activation strength per molecule).
For the physician or sophisticated user choosing between GHRH analogs, the decision framework should be driven by pharmacokinetic needs, regulatory context, and evidence quality — not by marketing claims about relative potency.
HIV-associated lipodystrophy: tesamorelin is the FDA-approved, evidence-based standard of care. No other GHRH analog has Phase 3 RCT data in this specific condition. HIV-associated NAFLD: the only GHRH analog with a Lancet-published RCT showing liver fat reduction and fibrosis prevention in HIV patients. Evidence-conscious practitioners prescribing off-label for non-HIV visceral fat reduction in adults who want the most rigorously studied compound with the strongest evidence base: tesamorelin's Phase 3 RCTs provide more confidence in mechanism and safety than any research chemical GHRH analog.
Cost: tesamorelin as a commercial pharmaceutical (Egrifta WR) is substantially more expensive than compounded sermorelin or compounded CJC-1295. The price differential can be 10-20x for the commercial product. Compounded tesamorelin (prepared by 503A pharmacies from research-grade bulk API) exists at lower prices but operates in the same regulatory gray zone as compounded sermorelin. Convenience: for physicians who primarily work with compounding pharmacies for their peptide prescriptions, sermorelin or CJC-1295 are more accessible and lower cost. Shorter half-life preference: some practitioners argue that sermorelin's 10-12 minute half-life produces the most physiologically natural GH pulsatility. Off-label general somatopause: the evidence difference between tesamorelin and sermorelin in the off-label non-HIV population is small because neither has Phase 3 data in that population — the choice becomes cost, convenience, and prescriber familiarity.
The Baker 2012 JAMA Neurology cognitive trial used tesamorelin (or a close equivalent GHRH analog) in older adults specifically. This gives tesamorelin a marginal evidence advantage for the cognitive application over sermorelin or CJC-1295, which have not been studied in cognitive function trials at this level of rigor. The advantage is Grade B evidence vs Grade E (community consensus) for the others — meaningful but not definitive. Whether the cognitive findings will be replicated in larger or more recent trials is an open question.
Clinical practice in anti-aging and longevity medicine has accumulated substantial observational experience with tesamorelin in non-HIV patients. The reported experience: improved sleep quality (nocturnal GH pulse amplification; typically reported within 1-2 weeks); reduced abdominal girth/tightening (noticeable at 4-8 weeks; CT or DEXA confirmation of VAT reduction at 12-16 weeks in some clinic protocols); improved energy levels (IGF-1-mediated metabolic effects); joint aches in some patients, particularly those with pre-existing musculoskeletal issues; modest glucose elevation in a subset, generally within clinical monitoring range. The time to meaningful VAT reduction at 2 mg/day in the anti-aging context: most practitioners expect 8-12 weeks for noticeable changes, 16-24 weeks for substantial measurable reduction.
Tesamorelin exists in two regulatory contexts: (1) Commercial pharmaceutical (Egrifta/Egrifta SV/Egrifta WR by Theratechnologies): FDA-approved for HIV lipodystrophy; bioequivalence and sterility standards guaranteed; expensive (tens of thousands of dollars annually at full price for the HIV indication; insurance coverage limited to approved indication in HIV patients). (2) Compounded tesamorelin from 503A pharmacies: prepared from bulk API; available with physician prescription for off-label use; significantly less expensive than commercial Egrifta; quality depends on pharmacy and API source; not FDA-approved as a drug product. For practitioners prescribing off-label in non-HIV patients, compounded tesamorelin is typically the access route. For HIV patients with the approved indication, commercial Egrifta may be covered by HIV-specialty insurance programs.
A practical consideration for off-label use in aging adults: the somatostatin feedback ceiling may limit tesamorelin's VAT reduction effects in adults who still have relatively normal GH pulsatility (which is more common in younger adults or those earlier in somatopause). The Phase 3 dramatic results occurred in HIV patients with documented GHRH-pituitary axis disruption — their blunted GH pulsatility meant large incremental GH was available to be restored. In a 45-year-old with partial somatopause and still-present GH pulses, the increment available is smaller. This is the pharmacological reason to expect smaller VAT effects in the off-label general population than the 15-18% seen in Phase 3. Community expectations calibrated to the Phase 3 numbers may be disappointed.
In the longevity medicine context, tesamorelin is frequently used as part of a broader hormonal optimization protocol rather than as a standalone compound. The most common co-prescriptions in anti-aging practice: testosterone replacement therapy (TRT) — tesamorelin's VAT reduction and IGF-1 elevation complement androgen-driven lean mass accretion; thyroid optimization — thyroid hormone and GH act synergistically on body composition; metformin or berberine — for the glucose monitoring concern, some practitioners pre-emptively combine tesamorelin with insulin sensitizers; BPC-157 or other healing peptides — for the joint/musculoskeletal side effects that some patients experience. There are no controlled trials evaluating any of these combinations with tesamorelin. The rationale is mechanistically coherent; the additive evidence is not established. In clinical practice, tesamorelin is the most evidence-supported GHRH analog available, and this attracts it into multi-compound protocols where it anchors the GH axis support role.
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism. 95(9):4291-4304. [The pivotal pooled Phase 3 analysis. LIPO-010 (n=412) + CTR-1011 (n=404). VAT -17%; IGF-1 +81%; lean mass increase; triglyceride reduction. Foundation of FDA approval.]
FDA prescribing information: Egrifta WR (tesamorelin for injection). Theratechnologies Inc. Approved March 2025. [Current label including the explicit statement that tesamorelin is not indicated for weight loss management and has a weight-neutral effect; contraindication in active malignancy; monitoring requirements.]
Stanley TL, Feldpausch MN, Oh J, Branch AD, Pessin JE, Sloane AJ, Bailey SM, Grunfeld C, Falutz JM, Mangili A, Delphin MA, Sax PE, Tien PC, Polak JF, Grinspoon SK. (Lancet HIV, 2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. [n=61; -37% hepatic fat; fibrosis progression 10% vs 35% placebo; only proven treatment for NAFLD in HIV. PMC6981288.]
Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 69(11):1420-1429. PMID 22869106. [GHRH analog improved executive function and verbal memory in adults 55+ with MCI; the key cognitive trial; inconsistently replicated.]
FDA approval of Egrifta WR (F8 formulation), March 25, 2025. Theratechnologies press release. [Weekly reconstitution; half injection volume; bioequivalence confirmed; marketed as Egrifta WR; replaces Egrifta SV in commercial distribution.]
Tesamorelin is the most evidence-backed GHRH analog in existence, and simultaneously the compound whose community use most consistently misrepresents what the evidence actually supports.
The central tension resolved: the Phase 3 trials are real, rigorously designed, and show genuine clinical benefit — 15-18% visceral fat reduction in HIV lipodystrophy is a meaningful clinical outcome supported by double-blind placebo-controlled data at scale. The Lancet HIV NAFLD trial is one of the more impressive compound-specific results in recent endocrinology research — preventing fibrosis progression in 90% vs 65% of patients is not a trivial effect. These results justify the FDA approval in the specific population studied. What they do not justify is the routine extrapolation to the anti-aging, somatopause, and general visceral obesity markets where most community/longevity clinic use occurs. The approved population had HIV-associated GH axis disruption creating a pharmacological opportunity that does not exist at the same magnitude in otherwise healthy adults. The prescribing label's own statement — 'not indicated for weight loss management as it has a weight-neutral effect' — is routinely omitted from clinic marketing materials.
The practical guidance: tesamorelin is a reasonable off-label choice for physicians managing visceral fat in non-HIV adults specifically because it has more clinical evidence than any research-chemical GHRH analog. The somatostatin feedback ceiling provides safety. The monitoring requirements (glucose, IGF-1) are manageable. The evidence for the specific indication should be communicated accurately — Grade B in non-HIV populations, not Grade A extrapolation from HIV trials. Anyone prescribing tesamorelin primarily for weight loss should read the label first.
— End of Tesamorelin —
THE PEPTIDE BIBLE | Tesamorelin | For Research & Educational Purposes Only
Tesamorelin (Egrifta, Egrifta SV, Egrifta WR): synthetic GHRH analog — full 44-amino acid endogenous GHRH sequence with trans-3-hexenoic acid conjugated to N-terminal tyrosine. MW ~5135 Da. N-terminal modification provides DPP-IV protection, extending functional half-life to ~26-38 minutes vs GHRH's rapid degradation. MECHANISM: GHRHR (Gs-coupled, cAMP/PKA) on anterior pituitary somatotrophs → pulsatile GH release → IGF-1 → visceral adipocyte lipolysis via GH-mediated HSL activation; preferential visceral over subcutaneous fat reduction (visceral adipocytes more beta-adrenergic sensitive); somatostatin feedback ceiling preserved. HEPATIC MECHANISM: GH stimulates hepatic beta-oxidation + reduces de novo lipogenesis + reduces portal fatty acid delivery (visceral fat → portal vein → liver). FDA APPROVAL: Egrifta (2010, Theratechnologies) → Egrifta SV (2019) → Egrifta WR/F8 (March 2025, weekly reconstitution). Approved indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Only FDA-approved GHRH analog. PHASE 3 EVIDENCE (Grade A — HIV lipodystrophy): LIPO-010 (n=412) + CTR-1011 (n=404) DBRPCT: 15-18% VAT reduction at 26 weeks; IGF-1 +81%; lean mass increase; triglyceride reduction. NAFLD TRIAL (Grade A — HIV-associated NAFLD): Stanley/Grunfeld, Lancet HIV 2019; n=61; DBRPC; 12 months; -37% hepatic fat; fibrosis progression 10% vs 35% placebo. COGNITIVE FUNCTION (Grade B): Baker 2012 JAMA Neurology; GHRH analog improved executive function/verbal memory in adults 55+ with MCI; 2024 HIV trial negative; inconsistent replication. NON-HIV OFF-LABEL (Grade B): one small 2025 preliminary study in metabolic syndrome; mechanism plausible; effect likely smaller than Phase 3 (less GH axis suppression than HIV/HAART). WEIGHT NEUTRAL: FDA label explicitly states 'not indicated for weight loss management as it has a weight-neutral effect.' DOSING: 2 mg/day SubQ; nightly preferred; no titration needed; continuous therapy standard. SAFETY: arthralgia; injection site reactions; peripheral edema; modest glucose/HbA1c elevation (monitor); active malignancy contraindicated; pregnancy contraindicated. MONITORING: baseline IGF-1, fasting glucose, HbA1c; on-therapy IGF-1 q3-6 months; glucose periodically. GHRH ANALOG POSITION: vs sermorelin (shorter t1/2, lower cost, compounded only, less evidence); vs CJC-1295 no DAC (similar t1/2, compounded, FDA-cited pituitary signal concern); vs CJC-1295 DAC (non-pulsatile, near-continuous, different mechanistic profile). WADA: S2 banned at all times. The central tension: the most evidence-backed GHRH analog in existence — whose rigorous clinical evidence is routinely over-extrapolated beyond the specific HIV population in whom it was established.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.